Welch Allyn gaining cardiopulmonary line with acquisition of Schiller America.
This article was originally published in The Gray Sheet
WELCH ALLYN TO EXPAND SALES FORCE BY 50% TO 60 REPS following the acquisition of Schiller America, which took effect Jan. 1. Announced Jan. 5, the move leaves an equal number of reps in Welch Allyn's core medical instruments business and its medical equipment operation.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.